Memorial Sloan Kettering is a 10,000+ person nonprofit cancer hospital and research institution running a complex clinical and research operation on Epic, with active adoption of Python, PyTorch, and cloud infrastructure (AWS, Databricks, dbt). The tech stack reveals a dual-track organization: clinical systems management (Epic, HL7, DICOM, LIMS) layered with modern data and ML tooling (Databricks, dbt, R, Tableau, Power BI), signaling movement toward genomic and translational research pipelines. Hiring velocity is accelerating with 65 roles posted in the last 30 days, skewed heavily toward healthcare and research staff, but notably thin on engineering and data talent—a structural gap given the genomic data processing and informatics expansion projects in flight.
Notable leadership hires: Chief Clinical Genetics Service
Memorial Sloan Kettering Cancer Center, founded in 1884, is one of the world's most respected cancer hospitals and research institutions, combining specialized patient care with translational and basic research conducted through its Sloan Kettering Institute. The organization operates across multiple geographies and service lines: clinical care teams, a research division spanning genomics and immunology, administrative operations, and an emerging informatics and data infrastructure function. Scale includes 10,000+ employees across the United States with some research hiring in South Sudan. The center is simultaneously managing complex clinical workflows (Epic-based) and building scalable infrastructure for genomic data, antibody validation, and imaging protocol development—requiring coordination across pathology, research, and engineering teams.
MSK uses Epic for clinical systems, Python and PyTorch for research and modeling, AWS and Databricks for data infrastructure, dbt for data transformation, and Tableau/Power BI for analytics. Clinical data management includes HL7, DICOM, and LIMS. Recently adopting Cursor for development workflows.
Active projects span scalable pipelines for genomic data processing, new immunohistochemistry (IHC) and in-situ hybridization (ISH) protocols with CLIA validation, endocrine-responsive breast cancer modeling, clinical support programs, and expanding informatics services—reflecting a research-to-clinic pathway.
Other companies in the same industry, closest in size